Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

NCT04444804 · clinicaltrials.gov ↗

COMPLETED

Status

22153

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Rivaroxaban (Xarelto, BAY 59-7939)
DRUG: LMWH and Phenprocoumon

Sponsor

Bayer